Therapy related late effects in pediatric patients with hodgkin lymphoma treated with ABVD protocol at national cancer institute, Cairo University and children cancer ospital Egypt 57357 /
Mustafa Mohamed Selim
Therapy related late effects in pediatric patients with hodgkin lymphoma treated with ABVD protocol at national cancer institute, Cairo University and children cancer ospital Egypt 57357 / ِِالأثار البعيدة المدى المرتبطة بعلاج الأطفال المصابين بورم هودجكين الغدد الليمفاوية وتم علاجهم ببرتوكول (إيه بى فى دى) فى المعهد القومى للأورام: جامعة القاهرة و مستشفى الأطفال مصر57573 Mustafa Mohamed Selim ; Supervised Mohamed Hani Hussein , Iman Abdelmokhales Sidhom , Zeinab Salah Selim - Cairo : Mustafa Mohamed Selim , 2020 - 280 P. : charts , facimiles ; 25cm
Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Pediatric oncology
Background/purpose Long-term Hodgkin Lymphoma (HL) survivors are at risk of developing a range of therapy-related complications that may present 10 -15 years after treatment. The primary goal of study is to estimate the frequency of late effects and to determine risk factors that may contribute to this. Methods We performed a cross-sectional study on HL survivors who were treated at National Cancer Institute, Cairo or Children Cancer Hospital Egypt 57357 with ABVD chemotherapy ± radiotherapy with a minimum 5 years follow up. Results Two hundred and eight patients were candidate. The cumulative incidence (CI) of cardiac toxicity (CT) at 5 and 9 years was 18.7% ± SD 2.7 and 43.3% ± SD 4.4, respectively. Preexisting cardiac abnormalities, cumulative anthracycline dose and end of treatment cardiac status are a strong predictor for late cardiotoxicity. Hypertension, was observed in about 31% of HL survivors. Young age (prepuberty) and obesity at time of treatment are important factors for hypertension. Thyroid abnormalities developed with a 5-year CI of 2% (95% CI 0.6% - 4.9%) while at 9-years the CI was 27.9% (95% CI 19% - 36%). Neck radiation therapy and the percentage of thyroid gland exposed to radiation are important risk factors.Obesity, was observed in 36% of HL survivors. High body mass index and older age (post-puberty) at the initial presentation are significant factors for obesity during the follow up. Endocrine hypogonadism was present in 22.5% of male survivors and 38% of female survivors. Disturbance of menstrual cycles was XII present in about one-third of female survivors. Furthermore, exposure to radiation therapy was associated with higher risk of irregular menstrual cycles. Abnormal pulmonary function tests were found in 43% and restrictive pattern was the most common type. Secondary cancers were founded in 3 patients (1.4%)
Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) Hodgkin Lymphoma survivors Late effects
Therapy related late effects in pediatric patients with hodgkin lymphoma treated with ABVD protocol at national cancer institute, Cairo University and children cancer ospital Egypt 57357 / ِِالأثار البعيدة المدى المرتبطة بعلاج الأطفال المصابين بورم هودجكين الغدد الليمفاوية وتم علاجهم ببرتوكول (إيه بى فى دى) فى المعهد القومى للأورام: جامعة القاهرة و مستشفى الأطفال مصر57573 Mustafa Mohamed Selim ; Supervised Mohamed Hani Hussein , Iman Abdelmokhales Sidhom , Zeinab Salah Selim - Cairo : Mustafa Mohamed Selim , 2020 - 280 P. : charts , facimiles ; 25cm
Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Pediatric oncology
Background/purpose Long-term Hodgkin Lymphoma (HL) survivors are at risk of developing a range of therapy-related complications that may present 10 -15 years after treatment. The primary goal of study is to estimate the frequency of late effects and to determine risk factors that may contribute to this. Methods We performed a cross-sectional study on HL survivors who were treated at National Cancer Institute, Cairo or Children Cancer Hospital Egypt 57357 with ABVD chemotherapy ± radiotherapy with a minimum 5 years follow up. Results Two hundred and eight patients were candidate. The cumulative incidence (CI) of cardiac toxicity (CT) at 5 and 9 years was 18.7% ± SD 2.7 and 43.3% ± SD 4.4, respectively. Preexisting cardiac abnormalities, cumulative anthracycline dose and end of treatment cardiac status are a strong predictor for late cardiotoxicity. Hypertension, was observed in about 31% of HL survivors. Young age (prepuberty) and obesity at time of treatment are important factors for hypertension. Thyroid abnormalities developed with a 5-year CI of 2% (95% CI 0.6% - 4.9%) while at 9-years the CI was 27.9% (95% CI 19% - 36%). Neck radiation therapy and the percentage of thyroid gland exposed to radiation are important risk factors.Obesity, was observed in 36% of HL survivors. High body mass index and older age (post-puberty) at the initial presentation are significant factors for obesity during the follow up. Endocrine hypogonadism was present in 22.5% of male survivors and 38% of female survivors. Disturbance of menstrual cycles was XII present in about one-third of female survivors. Furthermore, exposure to radiation therapy was associated with higher risk of irregular menstrual cycles. Abnormal pulmonary function tests were found in 43% and restrictive pattern was the most common type. Secondary cancers were founded in 3 patients (1.4%)
Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) Hodgkin Lymphoma survivors Late effects